Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.00 Analyst target: $2.02 Upside: 102.00%
American BriVision (Holding) Corporation, a clinical-stage biopharmaceutical company, develops drugs and medical devices to meet unmet medical needs in the United States.
See the full interactive analysis & chart →Informational only — not investment advice.